Tag: result

Toronto, ON, June 10, 2026 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (“Capstone” or the “Corporation”) (TSX:CSE.PR.A) announced today that it does not intend to exercise its right under the terms of its Cumulative 5-Year Rate Reset Preferred Shares, Series A (the “Series A shares”) to redeem all or part of the currently outstanding 3,000,000 Series A shares on July 31, 2026. As a result, subject to certain conditions, the holders of the Series A shares have the right to convert all or part of their Series A shares, on a one-for-one basis, into Cumulative Floating Rate Preferred Shares, Series B (the “Series B shares”) on July 31, 2026 (the “Conversion Date”) in accordance with the terms of the Series A shares.

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- ZOOZ Strategy Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today announced that its Board of Directors has authorized management to explore a range of strategic alternatives that could potentially complement the Company’s existing bitcoin treasury strategy and enhance long-term shareholder value.

NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and April 13, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026.